Tag:
Angiomax
Latest Headlines
Latest Headlines
Medicines Company, APP settlement includes manufacturing agreement
A fill/finish manufacturing agreement is part of the settlement between The Medicines Co. ($MDCO) and APP Pharmaceuticals ( $APPX ) over generic versions of The Medicines Co.'s lead product, Angiomax.
Medicines Co. seems to get win in decade-long Angiomax spat
The Medicines Company announced today that the period for the government to appeal the Aug. 3 court decision ordering the Patent and Trademark Office to consider a 2001 Angiomax (bivalirudin) patent
APP Pharma thwarted in Angiomax patent suit
Medicines Co. is another step closer to clearing its patent protection on its key money-earner Angiomax. The company has been fighting the U.S. Patent and Trademark Office to get it to reconsider its
Medicines Co. wins Angiomax fight with PTO
Remember the dust-up between Medicines Co. ( NASDAQ: MDCO ) and the U.S. Patent and Trademark Office? They've been fighting over the company's application for a patent extension on the blood thinner
Medicines Co. still fighting for Angiomax patent
In spite of a third rejection from the U.S. Patent Office, Medicines Co. CEO Clive Meanwell says he will pursue all options to extend its exclusive rights to the anticoagulant drug Angiomax that
Judge gives Medicines Co. another chance
Will The Medicines Company finally undo its patent-filing mishap? Apparently, a federal judge has taken pity on the company, which filed for its Hatch-Waxman patent extension on Angiomax one day too
Medicines Co. amps up Angiomax lobbying
The Medicines Company is lobbying Congress. No big surprise, right? Drugmakers have been ploughing record amounts of cash into health-reform advocacy on Capitol Hill. But in Medicines Co.'s case, the
Sanofi, AZ, Medicines Co. herald heart successes
There was plenty of news generated over the weekend at the big European Society of Cardiology meeting in Barcelona. In addition to the headlines for Boehringer and AstraZeneca, above, Sanofi Aventis
